DarioHealthDarioHealth (Nasdaq:DRIO) announced today that multiple research studies support its digital therapeutics for diabetes management.

New York-based DarioHealth presented the data from the new studies at the American Diabetes Association’s (ADA) 82nd Scientific Sessions in New Orleans. Two of the studies add to DarioHealth’s evidence supporting an integrated approach to managing multiple chronic conditions, while the third analyzed the impact across ethnicities of users living with type 2 diabetes.

Get the full story at our sister site, Drug Delivery Business News.